21. International Conference on Harmonisation. ICH Harmonised Tripar- tite Guideline. Good Clinical Practice. 1996. https://www.ich.org/ fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/ E6_R1_Guideline.pdf. Accessed June 8, 2017. 22. Marbury TC, Flint A, Jacobsen JB, Karsbøl JD, Lasseter K. Pharmaco- kinetics and tolerability of a single dose of semaglutide, a human GLP-1 analog, in subjects with and without renal impairment. Clin Pharmacokinet. 2017;56(11):1381-1390. 23. Giorda CB, Nada E, Tartaglino B. Pharmacokinetics, safety, and effi- cacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A system- atic review of the literature.Endocrine. 2014;46:406-419. 24. Flint A, Nazzal K, Jagielski P, Hindsberger C, Zdravkovic M. Influence of hepatic impairment on pharmacokinetics of the human GLP-1 ana- logue, liraglutide.Br J Clin Pharmacol. 2010;70:807-814. 25. Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential.Hepatology. 2005;41:1211-1219. 26. Kapitza C, Dahl K, Bonde Jacobsen J, Axelsen MB, Flint, A. The effects of once-weekly semaglutide on beta-cell function in subjects with type 2 diabetes. EASD abstract 754. 2016. 27. Hausner H, Karsbøl JD, Holst AG, et al. Effect of semaglutide on the pharmacokinetics of metformin, warfarin, atorvastatin and digoxin in healthy sbjects.Clin Pharmacokinet. 2017;56:1391-1401. https://doi. org/10.1007/s40262-017-0532-6. How to cite this article: Jensen L, Kupcova V, Arold G, Pettersson J, Hjerpsted JB. Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment. Diabetes Obes Metab . 2018;20:998 –1005. https://doi.org/10.1111/ dom.13186 JENSEN ET AL. 1005